| N | Total sample | Controlsa (n = 40) | Casesa (n = 39) | p-valueb |
---|---|---|---|---|---|
Age, median (range), y | 79 | 37 (16–84) | 37 (17–84) | 39 (16–83) | 0.56 |
Men, n (%) | 79 | 40 (50.6) | 20 (50.0) | 20 (51.3) | 0.9 |
Smoking, n (%) | 79 | 40 (50.6) | 26 (65.0) | 14 (35.9) | 0.01 |
Main diagnosis, n (%) | 79 | Â | Â | Â | 0.33 |
 Psychotic disorders (F20-F24; F28-F29) |  | 36 (45.6) | 17 (42.5) | 19 (48.7) |  |
 Schizoaffective disorders (F25) |  | 10 (12.7) | 6 (15.0) | 4 (10.3) |  |
 Bipolar disorders (F30–F31) |  | 18 (22.8) | 12 (30.0) | 6 (15.4) |  |
 Depressive disorders (F32–F33) |  | 8 (10.1) | 2 (5.0) | 6 (15.4) |  |
 Other |  | 7 (8.9) | 3 (7.5) | 4 (10.3) |  |
Psychotropic treatment group, n (%)c | 79 | Â | Â | Â | 0.74 |
 Low risk of WG |  | 13 (16.5) | 6 (15.0) | 7 (18.0) |  |
 Medium risk of WG |  | 42 (53.2) | 23 (57.5) | 19 (48.7) |  |
 High risk of WG |  | 24 (30.4) | 11 (27.5) | 13 (33.3) |  |
BMI, median (range), kg/m2 | 79 | Â | Â | Â | Â |
 Baseline |  | 23.1 (15.2–37.5) | 23.5 (17.1–36.5) | 21.9 (15.2–37.5) | 0.16 |
 First month |  | 23.9 (17.0–39.5) | 23.8 (17.1–36.5) | 24.1 (17.0–39.5) | 0.81 |
 p-valued |  |  < 10–4 |  < 10–4 |  < 10–4 |  |
WG, median (range), % |  | 2.4 (0–23.0) | 0.5 (0–2.4) | 7 (5.2–23.0) |  < 10–4 |
Metabolic syndrome prevalence, n (%)e | 51 | Â | Â | Â | Â |
 Baseline |  | 3 (5.9) | 3 (11.1) | 0 (0.0) | 0.09 |
 First month |  | 8 (15.7) | 4 (14.8) | 4 (16.7) | 0.86 |
 p-valued |  | 0.23 | 0.32 | 0.05 |  |
Global baseline (T0) methylation (β-value), mean (range), % | 79 | 61.78 (58.52–64.01) | 61.80 (58.52–64.01) | 61.77 (59.20–63.86) | 0.87 |
Global methylation (β-value) increase (T1–T0), mean (95%CI), % | 79 | 0.187 (0.185–0.190) | 0.201 (0.198–0.204) | 0.174 (0.170–0.177) |  < 2.2 × 10–16 |